natl health inv - NHI
NHI
Close Chg Chg %
84.34 -0.20 -0.23%
Closed Market
84.15
-0.20 (0.23%)
Volume: 238.33K
Last Updated:
Feb 6, 2026, 3:59 PM EDT
Company Overview: natl health inv - NHI
NHI Key Data
| Open $84.72 | Day Range 83.29 - 85.07 |
| 52 Week Range 64.80 - 85.07 | Market Cap $3.88B |
| Shares Outstanding 47.64M | Public Float 45.40M |
| Beta 0.68 | Rev. Per Employee N/A |
| P/E Ratio 26.56 | EPS $3.19 |
| Yield 432.00% | Dividend $0.92 |
| EX-DIVIDEND DATE Dec 31, 2025 | SHORT INTEREST N/A |
| AVERAGE VOLUME 216.60K |
NHI Performance
| 1 Week | 2.37% | ||
| 1 Month | 8.65% | ||
| 3 Months | 9.47% | ||
| 1 Year | 24.42% | ||
| 5 Years | 22.84% |
NHI Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
8
Full Ratings ➔
An error occurred while fetching the data.
An error occurred while fetching the data.
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 85.875 | |
| Number of Ratings | 8 | Current Quarters Estimate | 0.774 | |
| FY Report Date | 03 / 2026 | Current Year's Estimate | 3.333 | |
| Last Quarter’s Earnings | 0.78 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 3.013 | Next Fiscal Year Estimate | 3.53 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 2 | 2 | 5 | 4 |
| Mean Estimate | 0.77 | 0.84 | 3.33 | 3.53 |
| High Estimates | 0.79 | 0.88 | 3.50 | 3.76 |
| Low Estimate | 0.76 | 0.81 | 3.21 | 3.36 |
| Coefficient of Variance | 2.98 | 6.18 | 3.67 | 4.73 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 5 | 5 | 6 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 3 | 3 | 2 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Overweight | Overweight | Overweight |
SEC Filings for Natl Health Inv - NHI
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Natl Health Inv - NHI
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Apr 2, 2025 | Robert G. Adams Director | 365,031 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $54.73 per share | 19,978,146.63 |
| Apr 2, 2025 | Robert G. Adams Director | 375,031 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $57.76 per share | 21,661,790.56 |
| Apr 2, 2025 | Robert G. Adams Director | 342,096 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $74.7 per share | 25,554,571.20 |
| Apr 2, 2025 | Robert G. Adams Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 2, 2025 | Robert G. Adams Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 2, 2025 | Robert G. Adams Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 2, 2025 | Robert G. Adams Director | 355,031 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $53.41 per share | 18,962,205.71 |
| Mar 6, 2025 | Candice W. Todd Director | 10,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | David Louis Travis SVP/Chief Accounting Officer | 21,555 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | James R. Jobe Director | 10,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | Tracy M. J. Colden Director | 10,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | Kristin Sallee Gaines SVP/Chief Transaction Officer | 8,334 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | Kristin Sallee Gaines SVP/Chief Transaction Officer | 8,333 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | Kristin Sallee Gaines SVP/Chief Transaction Officer | 8,333 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | Kristin Sallee Gaines SVP/Chief Transaction Officer | 61,944 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | D. Eric Mendelsohn CEO and President; Director | 25,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | D. Eric Mendelsohn CEO and President; Director | 25,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | D. Eric Mendelsohn CEO and President; Director | 25,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | D. Eric Mendelsohn CEO and President; Director | 96,527 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | Robert A. McCabe Director | 10,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |